"These biomarkers are highly accurate and robust, up to 97 percent, and could be developed into an early screening test for all types of cancers. We find that early detection and prevention is key for the survival and quality of life of cancer patients. This could benefit patients in Hawai'i and around the world," said Lana Garmire, PhD, an assistant professor in the Cancer Epidemiology Program at the UH Cancer Center.
Garmire, a translational bioinformatics expert who is successful at obtaining competitive NIH grants, used a powerful data mining approach to search through thousands of cancer organ tumor samples and large data sets to find the panel of lincRNAs.
LncRNAs as Cancer Biomarkers
Garmire's findings published in EBiomedicine highlight lincRnas as the most recently discovered new class of RNA molecules. The advancement of technologies has enabled the identification of tens of thousands of new lincRNAs. Researchers found the molecules to be excellent candidates for cancer biomarkers. Compared to protein coding genes, lincRNAs expression patterns are more specific to particular tissues and developmental stages, and thus could be better biomarkers for cancers.
"We have worked on this study for the last two years, and are at the verge of discovering something very useful. Thanks to the High Performance Computing (HPC) facility at UH Manoa, we have been using a Big Data analytics approach to start our hypothesis with massive data evidence before validating it in the lab," said Garmire.
The panel of biomarkers has been approved as a provisional patent, and Garmire is working on securing licensing.